Inflammation: a Key Contributor to Heart Disease and Diabetes?

What this Trial Is About

This research aims to understand how inflammation is linked to heart disease, diabetes, and related metabolic conditions, focusing on both healthy individuals and severely obese patients scheduled for weight-loss surgery. It seeks to find out if certain treatments can change the inflammatory response related to obesity and cardiometabolic diseases and what factors influence individual differences in treatment responses. The study is observational and aims to support personalized treatment approaches by identifying who may benefit most from anti-inflammatory therapies. The study includes two groups: healthy adults with normal weight and obese adults undergoing bariatric surgery such as Roux-en-Y gastric bypass or sleeve gastrectomy. Participants will have baseline tests to assess their inflammatory response, tissue biopsies taken during surgery for detailed analysis including treatment exposure outside the body, and follow-up visits about one year after surgery to monitor long-term changes. Advanced molecular and imaging methods will be used to study blood and tissue samples, including fat, liver, muscle, and intestinal tissues. Participants will be involved through initial testing, providing tissue samples during surgery, and follow-up assessments a year later to track changes in inflammation and metabolism. Researchers will measure outcomes such as reactive oxygen species production in whole blood at enrollment and one year post-surgery. Data from clinical, molecular, and biochemical tests will be combined to predict how individuals respond to therapy. The study is designed to improve understanding of inflammation's role in cardiometabolic disease and to help develop more targeted treatments.

Inflammation's Impact on Heart Disease and Diabetes